Cannabinoids are found in the marijuana plant (cannabis sativa) and are said to be effective in pain management from pain symptoms such as multiple sclerosis, diabetic neuropathy, peripheral neuropathy and nausea and vomiting. A cannabinoid is one of a great collection of complex chemical compounds that naturally occur in the body and operates on major cannabinoid receptors in cells that mediates neurotransmitter release in the brain. Endogenous cannabinoids for these receptors include the endocannabinoid system, that are produced in the body by animals, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the plant cannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non psychotic effect. This paper will look at cannabinoids and their potential to treat bladder dysfunction.
Here is the full scientific article if you wish to download it.
Cannabinoids may provide a treatment for pelvic disorders
Cannabinoids are the active chemical constituents of Cannabis sativa (marijuana). The medical application of marijuana dates back to over 5,000 years. Cannabinoids make a very wide range of primary and peripheral impacts, some of which may have favorable clinical uses. The finding of cannabinoid receptors has spurred a massive enthusiasm within the pharmaceutical sector with the idea of benefiting on the effects of marijuana without the unwarranted psychotropic impacts on the primary and peripheral nervous network. This study illustrates an evaluation of the pharmacology of cannabinoids and their constituents. It evaluates the most recent literature on primary and peripheral cannabinoid receptors as associated with the effects on the lower urinary tract and the job of these receptors in standard and unnatural urinary tract abilities. It is transparent that cannabinoid receptors are existing in the lower urinary tract as well as spinal and greater primaries in cahoots with lower urinary tract regulation. Systemic cannabinoids have impacts on the lower urinary tract that might be allowed to become clinically applicable; however, a much higher knowledge of the actions of cannabinoid receptors in mediation of the human lower urinary tract is needed to hold advancement of novel cannabinoid agents for treatment of pelvic syndromes.
Proper urinary bladder functioning could be regulated by cannabinoids
The results depicted in this revaluation display that the RhoA/ROK pathway is crucial for the regulation of basal SM tone of the urinary bladder and acts as a normal final pathway of numerous contractile stimuli in bunnies, rats, mice, and pigs. More so, this pathway is upregulated in reaction to several of pathological conditions related with bladder SM disorder. Likewise, RhoA/ROK transmissioning is necessary for standard ureteral regulation and growth and is upregulated in reaction to a ureteral outlet blockade. Finally, clinical data on the application of ROK inducers should start to surface in the not so distant future and will need to be critically reviewed. Overall, cannabinoids could provide useful tools in the regulation of normal urinary bladder functioning. This could be massive for people with overactive bladders.